What Abcam does

Abcam is a Cambridge, UK-headquartered life science reagents company founded in 1998 that produces antibodies, ELISA kits, biochemical and cell-based assays, recombinant proteins, and cell lines for academic, biopharmaceutical, and in vitro diagnostics customers. Its core technology platforms include RabMAb® rabbit monoclonal antibodies (over 36,000 recombinant SKUs with 115,000+ publication citations), SimpleStep ELISA® kits covering 1,000+ targets, and the newer SimpleStep Ignite™ chemiluminescent immunoassay platform delivering 50× greater sensitivity and results in 55 minutes. The company differentiates through validation rigor — knock-out validation on 4,900 antibodies, batch-to-batch recombinant consistency, and an evidence base of 600,000+ scientific citations across its 60,000+ antibody catalog.

Abcam operates a hybrid go-to-market combining product-led e-commerce direct sales via abcam.com (with regional storefronts in China and Japan) and a dedicated enterprise sales team handling custom antibody development, bulk orders, and scheduled deliveries for biopharma accounts; a regional distributor network fills geographic gaps. Pricing is quote-based for catalog and custom products, with publicly available unit pricing on standard SKUs and a lab essentials value tier; revenue also flows from custom conjugation services and custom antibody/ELISA development projects. Distribution reaches the US (Waltham, MA headquarters for US operations; Eugene, OR manufacturing), the UK (Cambridge headquarters), and active markets in China, Japan, Germany, Singapore, and Canada.

In December 2023, Danaher Corporation acquired Abcam plc for approximately $5.7 billion, taking the company private and integrating it into Danaher's life sciences portfolio alongside Beckman Coulter, Leica Microsystems, and Molecular Devices. Post-acquisition, Abcam has continued to expand its technology and partnership footprint — joining the €60M+ LIGAND-AI Consortium (January 2026), signing a companion diagnostics MoU with QIAGEN Suzhou for the Chinese market (August 2025), launching SimpleStep Ignite™ ELISA (April 2026), and integrating its reagents into Molecular Devices and Molecular Instruments workflows. The company maintains its operational identity and CiteAb-recognized brand while operating under the Danaher Business System framework.

Name

Abcam

Legal name

Abcam Limited

Website

https://abcam.com

Company type

Private

Founded year

1998

Operating status

Operating

Headcount range

1,001–5,000 employees

Short description

Abcam manufactures and sells over 60,000 antibodies, ELISA kits, biochemical assays, and recombinant proteins to academic researchers, biopharmaceutical companies, and IVD manufacturers globally, operating as a wholly-owned subsidiary of Danaher Corporation since December 2023.

Ownership category

akta.pro rank

Product category

Life Science Research Reagents

NAICS

Biological Product (except Diagnostic) Manufacturing (325414), Research and Development in Biotechnology (except Nanobiotechnology) (541714)

SIC

Biological Products, (No Disgnostic Substances) (2836), Services-Commercial Physical & Biological Research (8731)

akta.pro primary industry

Antibody Discovery & Engineering Platforms (display tech, bispecifics, Fc engineering) (HLAAAIAB)

Keywords

• Antibody reagents
• Life science research
• ELISA immunoassays
• Protein detection reagents
• Recombinant antibodies

Headquarters

HQ city

Cambridge

HQ country

United Kingdom

HQ region

Europe

Offices3 records

Markets served

GTM type

B2B

Offering type

Hardware or Manufacturing

Cost components

Supply Chain, Personnel, Technology or R&D, Operations, Marketing or Sales, Infrastructure

Revenue model

1. Life Science Reagents and Antibodies: Abcam generates revenue through the sale of antibodies (primary, secondary, conjugated), proteins, ELISA kits, biochemical assays, cell-based assays, and related reagents for life science research.
2. Custom Development Services: Revenue generated from custom antibody development, custom conjugation services, and tailored solutions for specific research needs.

Pricing tiers

Go-to-market motion2 records

Distribution channels4 records

Marketing channels5 records

Core offering

Abcam develops, manufactures, and distributes a comprehensive portfolio of over 60,000 life science research products, including primary and secondary antibodies, recombinant proteins, ELISA kits, and biochemical and cell-based assays. The company also offers custom antibody development and conjugation services for researchers in academic, biopharmaceutical, and diagnostic applications.

Product overview

Abcam is a life science reagents company offering a comprehensive portfolio of over 60,000 antibodies, proteins, kits, and reagents for life science research. The core product portfolio includes Primary Antibodies (monoclonal, recombinant, polyclonal, and multiclonal varieties) supported by over 600,000 citations, Secondary Antibodies with various conjugates, and Conjugated Antibodies pre-labeled with fluorescent dyes (Alexa Fluor®, PE, APC, FITC) or enzymes (HRP, AP). The company offers ELISA kits including SimpleStep ELISA® kits and the newer SimpleStep Ignite™ chemiluminescent platform, plus Biochemical and Cell-Based Assays for metabolism and cell health research. Supporting products include Recombinant Proteins, Cell Lines, and Carrier-Free Antibodies for custom conjugation. Abcam provides Custom Antibody Development services and AI-powered research assistance through MollAI. The company operates as a Danaher company following the $5.7 billion acquisition completed in August 2023.

Differentiator

Problem solved

Functional benefit

Brands

• RabMAb: Rabbit monoclonal antibody technology platform known for high affinity and specificity
• SimpleStep ELISA
• SimpleStep Ignite ELISA
• MollAI
• RabMAb Recombinant Antibodies
• CiteAb Awards

Products and services

• Primary Antibodies Portfolio of over 60,000 highly cited antibodies (monoclonal, recombinant, polyclonal, multiclonal) for protein detection in life science research, validated across multiple applications and supported by over 600,000 citations.
• RabMAb® Rabbit Monoclonal Antibodies Rabbit monoclonal antibodies offering higher affinity and specificity than traditional mouse monoclonals, with over 36,000 recombinant antibodies available and KO validation.
• Secondary Antibodies HRP-conjugated, Alexa Fluor®, fluorescent, and other secondary antibodies for protein detection in Western blot, ELISA, flow cytometry, and other immunoassay applications.
• Conjugated Antibodies Pre-conjugated primary antibodies with fluorescent dyes, enzymes, or labels for direct protein detection without secondary antibody steps; over 13,000 products available.
• SimpleStep ELISA® Kits Simplified sandwich ELISA kits offering consistent, sensitive, and specific immunoassays across 1,000+ targets with single-wash protocols reducing workflow complexity.
• SimpleStep Ignite™ ELISA Next-generation chemiluminescent immunoassay platform delivering results in 55 minutes with 50× greater sensitivity and 35× broader dynamic range compared to traditional colorimetric ELISAs.
• Biochemical and Cell-Based Assays Metabolism assays, cell health assays, and enzyme activity assays for measuring cellular processes and biomarkers in research applications.
• Recombinant Proteins and Biochemicals Recombinant proteins, cytokines, growth factors, peptides, and blocking peptides for use as standards, controls, and functional reagents in research; plus biochemicals including inhibitors, antagonists, and agonists.
• Cell Lines and Lysates Extensively validated gene-edited cell lines and lysates for reliable experimental results in life science research.
• Custom Antibody Development and Conjugation Services Custom-engineered antibody conjugation and custom antibody/ELISA development services delivered by in-house expert teams for specialized research applications.
• Carrier-Free Antibodies Over 10,000 recombinant antibodies formulated without BSA, sodium azide, or glycerol at 1 mg/mL for flexible custom conjugation workflows with 100% recovery.

Quantifiable outcome

• 50x greater sensitivity and up to 35x broader measuring range with SimpleStep Ignite™ ELISA
• +2 more outcomes

Named customers3 records

Segments3 records

Ideal customer profiles3 records

Technology focussed Yes

API detail

Has API

No

API docs

API detail

Core technology

AI maturity

App detail

Integration3 records

AI capability2 records

Feature6 records

Partnerships

Four partnerships are on record, tiered core and major.

• LIGAND-AI Consortium (Structural Genomics Consortium, Pfizer, and 16 other partners)coreStrategic or Co-development Partner · 20 January 2026Abcam joined the LIGAND-AI project, a public-private partnership with €60 million+ budget led by the Structural Genomics Consortium and Pfizer. Abcam contributes its recombinant protein engineering and production capabilities to generate high-quality binding datasets for AI models predicting molecular binding for thousands of human proteins, supporting next-generation therapeutics targeting rare, neurological, and oncological conditions.
• Molecular InstrumentsmajorTechnology or Integration · 21 October 2025Announced broad compatibility of Molecular Instruments' HCR™ HiFi Encoder with Abcam's RabMAb® and mouse antibody portfolio. Collaboration enhances multiplex immunofluorescence and RNA imaging workflows by enabling detection of up to 10 targets simultaneously in a single sample.
• Molecular DevicesmajorTechnology or Integration · 10 October 2025Partnership to provide integrated biomarker discovery workflows combining Abcam's validated assay kits with Molecular Devices' automation-ready microplate readers and integrated data analysis software. Collaboration tested in a human ALT liver toxicity study demonstrating 4x more data in 384-well format compared to 96-well plates, reducing assay time to ~90 minutes with 60% less hands-on time.
• QIAGEN (Suzhou)coreStrategic or Co-development Partner · 7 August 2025QIAGEN and Abcam signed a strategic Memorandum of Understanding to co-develop companion diagnostic (CDx) and in vitro diagnostic (IVD) reagents and kits specifically targeting the Chinese market for pharmaceutical and clinical applications.

Scale indicators7 records

Recent moves7 records

Expansion highlights6 records

Direct peers

• Cell Signaling Technology: CST is the closest direct competitor to Abcam, specializing in high-quality, application-validated antibodies (especially for Western blot and IHC) with strong recombinant antibody platforms. CST and Abcam compete head-to-head in the academic and biopharma research markets across the same core target catalog.
• Bio-Rad Laboratories: Bio-Rad's Life Science segment offers antibodies, Western blot reagents, and protein standards that directly overlap with Abcam's catalog. Both companies serve academic and biopharma researchers with validated reagent kits and protein research tools.
• Bio-Techne (Novus Biologicals / R&D Systems): Bio-Techne's Novus Biologicals and R&D Systems brands compete directly with Abcam in primary antibodies, ELISA kits, and recombinant proteins, particularly in the biopharma and academic research segments. Both emphasize validated, application-specific reagents.
• Santa Cruz Biotechnology: Santa Cruz Biotechnology is a long-standing antibody supplier competing with Abcam in research antibodies, particularly for Western blot, IHC, and flow cytometry applications across academic and translational research customers.
• Atlas Antibodies: Atlas Antibodies specializes in highly validated, triple-immunogen affinity-purified polyclonal antibodies, including the Human Protein Atlas portfolio. It competes with Abcam in the premium, validation-heavy research antibody niche, particularly for IHC applications.

Broad incumbents

• Thermo Fisher Scientific (Invitrogen / Thermo Scientific Antibodies): Thermo Fisher offers a massive antibody and reagent portfolio through Invitrogen and other brands, alongside much broader life sciences instrumentation. It competes with Abcam across nearly every product category while also serving as a broad incumbent with deeper pockets and global distribution.
• MilliporeSigma (Merck KGaA Life Science): MilliporeSigma is one of the largest life science reagent suppliers globally, offering antibodies, biochemicals, and kits that overlap extensively with Abcam's portfolio. As part of Merck KGaA, it operates at greater scale and breadth across multiple life science verticals.
• BD Biosciences: BD Biosciences provides flow cytometry antibodies and reagents that overlap with Abcam's flow antibody portfolio. As a broad incumbent, BD combines reagent offerings with instruments and software platforms targeting immunology and cell biology research.

Emerging players

• GenScript: GenScript offers custom antibody services, recombinant proteins, and gene synthesis that overlap with Abcam's catalog and custom services. It is a credible emerging competitor, particularly in Asia and in the custom antibody development segment.
• Proteintech Group: Proteintech has grown rapidly as a direct competitor to Abcam in primary antibodies, with strong citation growth and a focus on KO-validated reagents. It is emerging as a credible global challenger, particularly in academic research and via direct e-commerce channels.

Market position

Strengths4 records

Weaknesses5 records

Competitive moat6 records

Key risks6 records

Key highlights6 records

Customer concentration

• Xx.com/abcam
• YouTubeyoutube.com/channel/UC17cyB7OIeKqTCUAPE8ZhFQ
• Facebookfacebook.com/abcam
• LinkedInlinkedin.com/company/abcam

Revenue estimate

Valuation estimate

Number of profiles

Profiles8 records

Subsidiaries1 record

Funding overview

Funding rounds3 records

Investors1 record

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A9 records

Investments1 record

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about Abcam